Adalimumab-induced Epstein-Barr virus-related lymphoproliferative disorder on FDG PET/CT Journal Article
| Authors: | Ward, J.; Noy, A.; Ulaner, G.; Riedl, C. |
| Article Title: | Adalimumab-induced Epstein-Barr virus-related lymphoproliferative disorder on FDG PET/CT |
| Abstract: | Adalimumab is a fully human chimeric tumor necrosis factor inhibitor used to treat immune-mediated disorders such as psoriatic arthritis. We present a 51-year-old woman with psoriatic arthritis on methotrexate and infliximab for 12 years. Adalimumab replaced infliximab because of worsening symptoms. Following 3 doses administered 1 week apart, rapidly enlarging cervical lymph nodes developed. Biopsy revealed Epstein-Barr virus-related polymorphic lymphoproliferative disorder. 18F-FDG PET/CT demonstrated widespread hypermetabolic lymphadenopathy; follow-up at 5 weeks off adalimumab revealed almost complete resolution of this adenopathy. This is most consistent with Epstein-Barr virus-related lymphoproliferative disorder secondary to tumor necrosis factor α inhibition. © 2018 Wolters Kluwer Health, Inc. All rights reserved. |
| Keywords: | 18f-fdg pet/ct; adalimumab; epstein barr virus-related lymphoproliferative disorder |
| Journal Title: | Clinical Nuclear Medicine |
| Volume: | 43 |
| Issue: | 5 |
| ISSN: | 0363-9762 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2018-05-01 |
| Start Page: | 344 |
| End Page: | 345 |
| Language: | English |
| DOI: | 10.1097/rlu.0000000000002054 |
| PROVIDER: | scopus |
| PUBMED: | 29538028 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 May 2018 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work